Clinical Trial Update: Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating third-party donor-derived CMVpp65-specific T cells for cytomegalovirus infection or persistent CMV viremia after allogeneic hematopoiet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection
• Cytomegalovirus Viremia

Drugs mentioned

• CMVpp65-specific T cells (CMV pp65-specific cytotoxic T lymphocytes)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: CMV Infection, Persistent CMV Viremia | Phase 2 | Status: COMPLETED | Results posted: 2024-10-17